Temodal (temozolomide) Post Marketing Surveillance Protocol.
Phase of Trial: Phase IV
Latest Information Update: 16 Dec 2013
At a glance
- Drugs Temozolomide (Primary)
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme
- 08 May 2012 Actual patient number is 682 according to ClinicalTrials.gov.
- 03 Jan 2012 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
- 03 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.